Clinical trials: Aquagenic Pruritus
Myeloproliferative Disorder
Clinical Characteristics of Aquagenic Pruritus in Patients With Myeloproliferative Neoplasms
Description of the characteristics of aquagenic pruritus expressed by patients suffering from myeloproliferative neoplasms. Prospective work based on the distribution of a dedicated questionnaire.
- Trial name
- PASYMPLE (NCT03688490)
- Volunteers
- 70 people
- Sponsor
- University Hospital, Brest
Deciphering Aquagenic Pruritus in Myeloproliferaitive Neoplasms
Aquagenic Pruritus in Myeloproliferative Neoplasms
Description of the characteristics of aquagenic pruritus expressed by patients suffering from myeloproliferative neoplasms. Prospective work based on the distribution of a dedicated questionnaire.
- Trial name
- PANAM (NCT04018209)
- Where
- 11 sites in France
- Volunteers
- 170 people
- Sponsor
- University Hospital, Brest
Myeloproliferative Disorder, Aquagenic Pruritus
Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms
Phase 3, randomized prospective study, double blind-double placebo, testing oral therapies APREPITANT versus HYDROXYZINE in patients followed for myeloproliferative neoplasms and suffering of persistent aquagenic pruritus.
- Trial name
- APHYPAP (NCT03808805)
- Testing
- Aprepitant 80 mg, Hydroxyzine 25mg
- Where
- 11 sites in France
- Volunteers
- 63 people
- Sponsor
- University Hospital, Brest